NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.1 Cytotoxic drugs > 8.1.5 Other antineoplastic drugs > Multiple myeloma - bortezomib (induction therapy) NICE TAG TA311

Multiple myeloma - bortezomib (induction therapy) NICE TAG TA311

1.1 Bortezomib is recommended as an option within its marketing authorisation, that is, in combination with dexamethasone, or with dexamethasone and thalidomide, for the induction treatment of adults with previously untreated multiple myeloma, who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.

https://www.nice.org.uk/guidance/TA311

Site by Devopa
© Copyright 2020 NHS. All rights reserved.